Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in preclinical models of aggressive lymphomas

Autor: Gaudio, E., Tarantelli, C., Kwee, I., Barassi, C., Bernasconi, E., Rinaldi, A., Ponzoni, M., Cascione, L., Targa, A., Stathis, A., Goodstal, S., Zucca, E., Bertoni, F. *
Zdroj: In Annals of Oncology June 2016 27(6):1123-1128
Databáze: ScienceDirect